AbbVie
ABBV
$285.42
+0.71%
AbbVie is a research-driven biopharmaceutical company whose portfolio spans immunology (Skyrizi, Rinvoq, and the legacy Humira franchise), oncology (Imbruvica, Venclexta), neuroscience (Botox Therapeutic, Vraylar, Ubrelvy, Qulipta), and medical aesthetics (Botox Cosmetic, Juvederm), following its 2013 spin-off from Abbott and the transformative 2020 Allergan acquisition. It is a large-cap pharma heavyweight with a market capitalization of roughly $405 billion and approximately 57,000 employees, distinguished by an unusually concentrated growth engine in two immunology assets and a dividend Aristocrat-style capital return profile. The current investor narrative centers on the durability of the Skyrizi/Rinvoq growth ramp as it more than offsets Humira biosimilar erosion, the credibility of the post-Cerevel and ImmunoGen pipeline following the recent FDA approval of the Parkinson's drug Juvmo, and the sustainability of a dividend whose payout ratio exceeds reported earnings. Debate also hinges on whether the stock's strong relative strength reflects a durable re-rating of the growth outlook or an overextended defensive rotation into pharma.…
ABBV
AbbVie
$285.42
Related headlines
Investment Opinion: Should I buy ABBV Today?
The synthesized recommendation is Hold, with a bias toward accumulating on pullbacks. The core thesis is that AbbVie's growth engine (Skyrizi/Rinvoq at 47% of revenue, 10.16% YoY growth) and strong free cash flow ($19.68 billion) justify a premium valuation, but the stock already trades above the average analyst target of $282.61, limiting near-term upside. The consensus rating is 'buy' (mean 1.7), but the implied return to the average target is roughly -1.0%, suggesting the easy money has been made.
Supporting evidence includes: 1) forward PE of 17.60x versus a 10-25% premium to the 14-16x sector norm, which is defensible given 10.16% revenue growth and 74.74% gross margin; 2) revenue trajectory improving sequentially from $15.00 billion in Q1 2026 to $16.99 billion in Q2 2026; 3) operating margin of 37.86% and gross margin of 74.74%, both above sector averages; 4) free cash flow TTM of $19.68 billion covering dividends and debt repayment; and 5) analyst high target of $328 implying 15% upside if pipeline catalysts deliver.
Key risks that could invalidate the thesis include: 1) a deceleration in Skyrizi/Rinvoq growth below 10% YoY, which would pressure the premium multiple; 2) dividend coverage concerns if free cash flow declines, given the 2.76x payout ratio; and 3) pipeline setbacks, particularly with Juvmo's launch. The rating would upgrade to Buy if the stock pulls back to the $250-$260 support zone (roughly 9-12% downside) or if analyst targets are revised upward above $300. It would downgrade to Sell if revenue growth falls below 5% or if free cash flow drops below $15 billion. Relative to history and peers, the stock appears fairly valued to modestly overvalued, with the market pricing in optimistic growth expectations.
Sign up to view all
ABBV 12-Month Price Forecast
The forward-looking view is neutral with medium confidence. AbbVie's growth trajectory is solid, with Skyrizi/Rinvoq driving 10.16% revenue growth and free cash flow of $19.68 billion supporting the dividend. However, the stock trades above the average analyst target and at a premium multiple, suggesting much of the good news is priced in. The Juvmo approval adds a potential catalyst, but execution risk remains. I would upgrade to bullish if the stock pulls back to the $250-$260 support zone or if analyst targets are revised upward above $300. I would downgrade to bearish if revenue growth decelerates below 5% or if free cash flow falls below $15 billion.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on AbbVie's 12-month outlook, with a consensus price target around $282.61 and implied upside of -1.0% versus the current price.
Average Target
$282.61
0 analysts
Implied Upside
-1.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$200 - $328
Analyst target range
Coverage is deep and constructive, with 28 analysts and a consensus recommendation of "buy" (mean rating of 1.7 on a 1-to-5 scale where 1 is a strong buy), and an average target price of $282.61, which sits essentially at the current $285.42 price, implying roughly -1.0% downside to consensus. That flat implied return is notable: the stock has already run past the average analyst target, which typically signals either that estimates and targets are due for upward revision or that the shares have become tactically extended relative to sell-side models. Consensus 2027 EPS of $20.96 (range $20.32 to $21.40) and revenue of $85.27 billion (range $83.24 billion to $86.63 billion) underpin the forward PE of 17.60x and suggest analysts expect continued mid-to-high single-digit top-line growth with margin expansion. The target range of $200.00 to $328.00 is wide, spanning roughly 46% around the average, which signals meaningful dispersion in assumptions: the $328 high target likely embeds multiple expansion toward 20x-plus forward earnings on accelerating Skyrizi/Rinvoq penetration and Juvmo ramp, while the $200 low target appears to price in Humira erosion, pipeline setbacks, or margin compression from drug pricing pressure. Institutional ratings show a clear upgrade bias, with Wolfe Research moving to Outperform from Peer Perform on August 13, 2026, Erste Group moving to Buy from Hold on August 5, 2026, and HSBC, Piper Sandler, Wells Fargo, Evercore ISI, Berenberg, and Guggenheim all reiterating Buy or Overweight ratings through September 2026, with BNP Paribas the lone Neutral holdout. The combination of a wide target spread and a recent cluster of upgrades suggests conviction is rising but not yet uniform, and the fact that the average target is below the current price is the single most important near-term signal for investors weighing entry at these levels.
Drowning in data?
Find the real signal!
Bulls vs Bears: ABBV Investment Factors
The bull case currently has stronger evidence: revenue growth of 10.16% YoY, Skyrizi/Rinvoq at 47% of revenue, $19.68 billion in free cash flow, and a consensus buy rating with recent upgrades all support the growth narrative. However, the bear case is not without merit, as the stock trades above the average analyst target of $282.61, carries a 2.76x payout ratio, and sits near its 52-week high with limited headroom. The single most important tension is whether the Skyrizi/Rinvoq ramp can sustain mid-teens growth and drive earnings normalization sufficient to justify the premium multiple, or whether the stock has already priced in this success and is due for a consolidation. Resolution of this debate will likely hinge on upcoming earnings and pipeline execution, particularly the Juvmo launch and any update to consensus targets.
Bullish
- Skyrizi/Rinvoq now 47% of revenue: Skyrizi at $5.51 billion and Rinvoq at $2.53 billion together generated roughly $8.03 billion, or about 47% of Q2 2026 revenue, while Humira has eroded to just $756 million. This confirms the post-Humira transition is largely complete and the growth engine is now concentrated in two assets with strong momentum.
- Revenue growth accelerating to 10.16% YoY: Q2 2026 revenue of $16.99 billion grew 10.16% year-over-year versus $15.42 billion in Q2 2025, and the sequential trend from $15.00 billion in Q1 2026 is constructive. This mid-teens growth exceeds the large-cap pharma norm and supports the forward PE of 17.60x.
- Free cash flow of $19.68 billion TTM: Free cash flow TTM is a robust $19.68 billion, with Q2 2026 operating cash flow of $3.44 billion comfortably covering $3.07 billion of dividends and $2.00 billion of debt repayment. This cash generation underpins the 2.88% dividend yield and deleveraging capacity.
- Juvmo approval adds $5 billion peak sales: The FDA approval of Juvmo for Parkinson's disease validates the Cerevel acquisition and adds a potential $5 billion peak-sales drug to the neuroscience franchise, which already includes Botox Therapeutic at $1.04 billion and Vraylar at $1.07 billion. This provides a new growth leg beyond immunology.
Bearish
- Stock trading above average analyst target: The average analyst target of $282.61 sits below the current price of $285.42, implying roughly -1.0% downside to consensus. This is a tactical warning that the stock has run past sell-side models and may be due for a pause or estimate revisions.
- Dividend payout ratio of 2.76x earnings: The payout ratio of 2.76x reported earnings highlights that the 2.88% dividend yield is covered by cash flow but not by GAAP net income, which has been depressed by one-time charges. Any cash flow deterioration would pressure the dividend, a key risk for income investors.
- Negative book equity and leveraged balance sheet: Debt-to-equity of -21.12 and PB of -123.96 reflect accumulated deficit-driven negative book equity, while the current ratio of 0.67 indicates tight liquidity. This capital-return-heavy structure leaves limited buffer if cash flow disappoints.
- Valuation premium to sector: The forward PE of 17.60x represents a roughly 10-25% premium to the large-cap pharma norm of 14-16x, while EV/EBITDA of 26.61x and PS of 6.63x are elevated. This leaves little room for error if growth decelerates or drug pricing pressure intensifies.
ABBV Technical Analysis
AbbVie is in a sustained, well-established uptrend, with the shares up 25.81% over the trailing year and 24.47% year-to-date, materially outpacing the S&P 500's 15.53% and 11.93% respective gains. At $285.42, the stock is trading at approximately 94.6% of its 52-week range of $190.75 to $291.40, a positioning that signals strong momentum but also meaningful proximity to overextension, with only about 2.1% of headroom to the prior high. The 19.23% maximum drawdown over the period indicates the advance has not been linear, but the recovery to near-highs confirms buyers have consistently absorbed pullbacks. Short-term momentum is accelerating rather than fading: the stock has gained 8.73% over the past month and 12.15% over three months, with the one-month gain far exceeding the 1.22% SPY advance and producing a 7.51 percentage-point relative-strength spread. The six-month change of 36.97% versus SPY's 7.48% represents a 29.49-point relative-strength advantage, the strongest reading across all measured windows, which suggests institutional accumulation rather than a retail-driven spike. Because the one-month, three-month, and one-year trends are all positive and aligned, there is no bearish divergence to flag; instead, the risk is vertical extension, and the 2.02-point daily gain on the latest session (up 0.71%) on volume of roughly 5.78 million shares shows no sign of distribution. Key resistance sits at the 52-week high of $291.40, roughly $6 above the current price; a clean breakout would confirm the uptrend and likely invite momentum and trend-following capital, while failure there could produce a double-top-style pullback. Initial support is anchored at the 52-week low of $190.75, with intermediate support likely in the $250-$260 zone where the stock consolidated in July and August; a break below that band would neutralize the bullish structure. The beta of 0.228 is exceptionally low, implying the stock moves roughly 77% less than the market, which historically reflects defensive pharma characteristics and supports larger position sizing for volatility-targeted portfolios, though it also means the stock's recent outperformance is idiosyncratic rather than market-driven.
Beta
0.23
0.23x market volatility
Max Drawdown
-19.2%
Largest decline past year
52-Week Range
$191-$291
Price range past year
Annual Return
+25.8%
Cumulative gain past year
| Period | ABBV Return | S&P 500 |
|---|---|---|
| 1m | +8.7% | +0.2% |
| 3m | +12.2% | +2.9% |
| 6m | +37.0% | +8.4% |
| 1y | +25.8% | +14.9% |
| ytd | +24.5% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ABBV Fundamental Analysis
Revenue is growing at a healthy clip, with Q2 2026 revenue of $16.99 billion representing 10.16% year-over-year growth versus $15.42 billion in Q2 2025, and the sequential trend is constructive: $13.34 billion in Q1 2025, $15.42 billion in Q2 2025, $15.78 billion in Q3 2025, $16.62 billion in Q4 2025, $15.00 billion in Q1 2026, and $16.99 billion in Q2 2026. The segment mix shows the growth engine clearly: Skyrizi at $5.51 billion and Rinvoq at $2.53 billion together account for roughly $8.03 billion, or about 47% of quarterly revenue, while Humira has eroded to just $756 million, confirming the successful transition away from the patent-cliff asset. Neuroscience is the second pillar, with Botox Therapeutic at $1.04 billion, Vraylar at $1.07 billion, Ubrelvy at $392 million, and Qulipta at $350 million, and the Juvmo approval adds a potential new leg to that franchise. Profitability is robust but volatile at the GAAP line: Q2 2026 net income was $3.61 billion on a 21.27% net margin, with gross margin of 74.74% and operating margin of 37.86%, while the trailing twelve-month net margin of 6.91% and trailing PE of 96.4x are distorted by prior-period charges, including a Q1 2026 net income of only $699 million and a Q3 2025 net income of $186 million. Gross margin has been stable to improving, moving from 71.88% in Q1 2026 to 74.74% in Q2 2026 and 72.61% in Q4 2025, which is consistent with a high-margin specialty pharma mix and above the roughly 70% level typical for large-cap biopharma. Balance sheet and cash flow metrics require careful reading: free cash flow TTM is a strong $19.68 billion, but the current ratio of 0.67 and debt-to-equity of -21.12 (negative because of accumulated deficit-driven negative book equity, with PB at -123.96) indicate a leveraged, capital-return-heavy structure rather than distress. Q2 2026 operating cash flow was $3.44 billion against $3.07 billion of dividends paid and $2.00 billion of debt repayment, and the payout ratio of 2.76x reported earnings (0.85x on the historical-ratio basis) highlights that the 2.88% dividend yield is covered by cash flow but not by GAAP net income, a key risk to monitor.
Quarterly Revenue
$17.0B
2026-06
Revenue YoY Growth
+10.2%
YoY Comparison
Gross Margin
74.7%
Latest Quarter
Free Cash Flow
$19.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ABBV Overvalued?
Because trailing net income is positive but heavily distorted by one-time charges, the trailing PE of 96.4x is not the right anchor; the forward PE of 17.60x against consensus EPS of $20.96 is the more meaningful metric, and the enormous gap between trailing and forward multiples implies the market expects a sharp earnings normalization as charges roll off and Skyrizi/Rinvoq scale. On a sales basis, the PS ratio of 6.63x and EV/Sales of 8.78x are the cleaner cross-checks, while EV/EBITDA of 26.61x and PCF of 21.30x suggest the stock is priced at a premium to the broad market. Peer comparison is constrained because the provided valuation dataset does not include an explicit industry-average multiple; however, against the large-cap pharma norm of roughly 14-16x forward earnings, the 17.60x forward PE represents a modest premium of approximately 10-25%, which is defensible given 10.16% revenue growth and a 74.74% gross margin that exceed the sector average. The 6.63x PS ratio versus a historical range that has oscillated between roughly 13x and 27x in the historical-ratios data (with the most recent Q2 2026 reading at 26.23x on a different calculation basis) places the stock toward the upper end of its own band, consistent with the market pricing in optimistic Skyrizi/Rinvoq and pipeline expectations rather than deep value. The negative PB of -123.96 and PEG of -77.13 are artifacts of negative book equity and distorted earnings and should be disregarded as valuation signals; the 2.88% dividend yield provides a modest valuation floor but is not sufficient alone to justify the current multiple.
PE
96.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 15x~139x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
26.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the company's leveraged, capital-return-heavy structure. The current ratio of 0.67 indicates tight short-term liquidity, while negative book equity (PB of -123.96) and debt-to-equity of -21.12 reflect an accumulated deficit from acquisitions and buybacks. The dividend payout ratio of 2.76x reported earnings means the 2.88% yield is covered by free cash flow ($19.68 billion TTM) but not by GAAP net income, leaving little cushion if cash flow deteriorates. Additionally, revenue concentration is high: Skyrizi and Rinvoq account for roughly 47% of Q2 2026 revenue, so any slowdown in these two assets would disproportionately impact the top line.
Market and competitive risks include valuation compression and drug pricing pressure. The forward PE of 17.60x represents a 10-25% premium to the large-cap pharma norm of 14-16x, and EV/EBITDA of 26.61x is elevated, leaving room for multiple contraction if growth decelerates. The beta of 0.228 is exceptionally low, implying the stock is defensive and less sensitive to market swings, but this also means recent outperformance is idiosyncratic and could reverse if defensive rotation fades. Competitive threats include Humira biosimilar erosion (already down to $756 million) and potential pricing pressure from Medicare negotiations or new entrants in immunology.
Worst-case scenario: a combination of slower Skyrizi/Rinvoq growth, pipeline setbacks (e.g., Juvmo launch disappointing), and dividend coverage concerns could trigger a de-rating. The 52-week low of $190.75 represents a 33.2% decline from the current $285.42, and the analyst low target of $200.00 implies roughly 30% downside. A realistic adverse scenario could see the stock retest the $200-$210 range, a loss of 26-30%, if earnings fail to normalize and the payout ratio remains stretched.
FAQ
The key risks are: 1) Financial: dividend payout ratio of 2.76x earnings and a current ratio of 0.67 indicate tight coverage and liquidity, ranking as the most severe; 2) Competitive: Skyrizi/Rinvoq represent 47% of revenue, so any slowdown in these two assets would disproportionately impact growth; 3) Macro/regulatory: drug pricing pressure and Medicare negotiation could compress margins; 4) Company-specific: pipeline setbacks, particularly with the Juvmo launch, could undermine the growth narrative. The stock's low beta of 0.228 makes it defensive, but also means it may lag in a strong market.
The 12-month forecast has three scenarios: bull case (25% probability) targeting $310-$328, driven by Skyrizi/Rinvoq beats and Juvmo ramp; base case (55% probability) targeting $270-$295, assuming steady execution and earnings normalization; and bear case (20% probability) targeting $200-$250, reflecting growth deceleration and multiple compression. The base case is most likely, with the key assumption being that Skyrizi/Rinvoq combined revenue grows at least 15% YoY and free cash flow remains above $18 billion. The average analyst target of $282.61 aligns with the base case.
ABBV appears fairly valued to modestly overvalued. The forward PE of 17.60x compares to a large-cap pharma norm of 14-16x, a 10-25% premium, while the PS ratio of 6.63x and EV/EBITDA of 26.61x are elevated. The trailing PE of 96.4x is distorted by one-time charges and not meaningful. Relative to its own history, the PS ratio is toward the upper end of its range, suggesting the market is pricing in optimistic growth expectations. The 2.88% dividend yield provides a modest floor, but the valuation implies the market expects continued mid-to-high single-digit revenue growth and margin expansion.
From a risk/reward perspective, ABBV is a reasonable buy for long-term income and growth investors, but the current entry point is not optimal. The stock trades at $285.42, above the average analyst target of $282.61, implying roughly -1.0% downside to consensus, and sits near its 52-week high of $291.40. The forward PE of 17.60x is a 10-25% premium to the sector, which is justified by 10.16% revenue growth and a 74.74% gross margin. The biggest downside risk is a retest of the $200-$250 range if growth decelerates, representing 12-30% downside. Therefore, it is a good buy for investors with a long-term horizon who can tolerate near-term volatility, especially on a pullback to the $250-$260 support zone.
ABBV is best suited for long-term investment, given its defensive characteristics (beta of 0.228), dividend yield of 2.88%, and stable earnings visibility from a diversified pharmaceutical portfolio. Short-term trading is less attractive due to the stock's low volatility and current proximity to its 52-week high, which limits near-term upside. A suggested minimum holding period is 2-3 years to allow for the full realization of the Skyrizi/Rinvoq growth ramp, Juvmo launch, and pipeline maturation. Income investors may hold indefinitely for the dividend, while growth investors should monitor quarterly earnings for signs of deceleration.